Protein Degradation Systems as Antimalarial Therapeutic Targets
Related Experiment Video
Updated: Feb 27, 2026
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Caroline L Ng1, David A Fidock2, Matthew Bogyo3
1Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, USA.
Abstract:
Artemisinin (ART)-based combination therapies are the most efficacious treatment of uncomplicated Plasmodium falciparum malaria. Alarmingly, P. falciparum strains have acquired resistance to ART across much of Southeast Asia. ART creates widespread protein and lipid damage inside intraerythrocytic parasites, necessitating macromolecule degradation. The proteasome is the main engine of Plasmodium protein degradation. Indeed, proteasome inhibition and ART have shown synergy in ART-resistant parasites. Moreover, ubiquitin modification is associated with altered parasite susceptibility to multiple antimalarials. Targeting the ubiquitin-proteasome system (UPS), therefore, is an attractive avenue to combat drug resistance. Here, we review recent advances leading to specific targeting of the Plasmodium proteasome. We also highlight the potential for targeting other nonproteasomal protein degradation systems as an additional strategy to disrupt protein homeostasis.
Insights
Artemisinin resistance in malaria parasites is a growing problem. Targeting protein degradation pathways, like the proteasome, shows promise for overcoming drug resistance.
Area of Science:
- Malariology
- Molecular Parasitology
- Drug Resistance
Background:
- Artemisinin-based combination therapies (ART) are effective against uncomplicated Plasmodium falciparum malaria.
- Drug resistance to ART is emerging in Southeast Asia, necessitating new treatment strategies.
- ART induces significant protein and lipid damage in parasites, requiring efficient degradation mechanisms.
Purpose of the Study:
- To review advances in specifically targeting the Plasmodium proteasome.
- To explore the potential of targeting other protein degradation systems.
- To combat ART resistance by disrupting parasite protein homeostasis.
Main Methods:
- Review of recent scientific literature on Plasmodium proteasome targeting.
- Analysis of the role of the ubiquitin-proteasome system (UPS) in antimalarial drug susceptibility.
- Exploration of non-proteasomal protein degradation pathways.
Main Results:
- Proteasome inhibition demonstrates synergy with ART in resistant parasites.
- Ubiquitin modification influences parasite susceptibility to antimalarials.
- Targeting the UPS is a viable strategy against drug-resistant malaria.
Conclusions:
- Specific targeting of the Plasmodium proteasome is a promising approach to combat ART resistance.
- Disrupting protein homeostasis via UPS or other degradation systems offers a new avenue for antimalarial drug development.
Related Concept Videos
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
02:58Regulated Protein Degradation
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...